title: Current Options for the Therapy of Chronic Hepatitis B Infection.
abstract: Until recently the only available treatment for chronic hepatitis B was interferon-alpha. Over the past few years a new class of antiviral has become available, the reverse transcriptase inhibitors. Lamivudine is a nucleoside analogue reverse transcriptase inhibitor that was recently approved in many countries for the treatment of hepatitis B. Despite the potent action of lamivudine, the development of new antivirals and new strategies to treat hepatitis B are still the major goal. We review the latest options for therapy of chronic hepatitis B, including combination strategies that could be an approach to improving the response rate of antivirals.
authors: Department of Gastroenterology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. Omata-2im@h.u-tokyo.ac.jp.
authors: Suzane
authors: S
authors: Kioko Ono-Nita
authors: Naoya
authors: N
authors: Kato
authors: Yasushi
authors: Y
authors: Shiratori
authors: Masao
authors: M
authors: Omata